Actively Recruiting
Real-world Study of Dostarlimab Treatment for Adults With dMMRMSI-H Stage II-III Locally Advanced Rectal Cancer
Led by National Cancer Institute, Naples · Updated on 2025-12-08
50
Participants Needed
2
Research Sites
47 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are studying the real-world effectiveness and safety of neoadjuvant dostarlimab in patients with locally advanced rectal cancer LARC who have dMMRMSI-H tumors. This observational, retrospective-prospective, multicenter trial focuses on patients included in the AIFA monitoring registry for dostarlimab use in this condition. The study aims to describe clinical outcomes and safety of dostarlimab treatment in a real-world setting. Participants receive dostarlimab at a dose of 500 mg intravenously every three weeks for up to nine cycles over a six-month period. The study includes both a retrospective part for patients treated since November 2023 and a prospective part with patients receiving dostarlimab according to Italian regulations. The main treatment outcome is the objective response rate measured after 3, 6, and 9 cycles. During the study, patients are monitored for treatment response, including complete and near-complete clinical responses, surgery rates, and pathological response. Safety is tracked through adverse event reporting at each cycle. Additional outcomes include event-free survival, organ preservation, time to distant recurrence, and overall survival up to 12 months. Data collection involves clinical evaluations and central radiological review to assess treatment activity and safety throughout the trial period.
CONDITIONS
Brief Title
Real-world Efficacy and Safety of Neoadjuvant Dostarlimab in Patients With dMMR/MSI-H Locally Advanced Rectal Cancer
Research Team
M
Maria Carmela Piccirillo, MD
P
Piera Gargiulo, MD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here